Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

详细信息    查看全文

• 作者：Hao-Cheng Chen ; Chien-Da Huang ; Erin Chang ; Han-Pin Kuo
• 关键词：Omalizumab ; Asthma ; Population ; based database ; Cohort study ; Real ; life setting
• 刊名：BMC Pulmonary Medicine
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：552 KB
• 参考文献：1.National Asthma Education and Prevention Program. Expert panel report III: Guidelines for diagnosis and management of asthma. 2007, US Department of Health and Human Services, National Institutes of Health.
  2.Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–9.PubMed CrossRef
  3.Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.PubMed PubMedCentral CrossRef
  4.Price D. The use of omalizumab in asthma. Prim Care Respir J. 2008;17:62–72.PubMed CrossRef
  5.Murphy P, Hillman T, Rajakulasingam K. Therapeutic targets for persistent airway inflammation in refractory asthma. Biomed Pharmacother. 2010;64:140–5.PubMed CrossRef
  6.The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470–7.CrossRef
  7.Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32–9.PubMed CrossRef
  8.Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–16.PubMed CrossRef
  9.Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy. 2007;62:1175–81.PubMed CrossRef
  10.Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65:56–60.PubMed CrossRef
  11.Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma. 2011;48:387–92.PubMed CrossRef
  12.Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pul Pharmaco Therap. 2012;25:77–82.CrossRef
  13.Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al. Pharmacoepidemiology of A Xolair Study G: Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143:398–405.PubMed CrossRef
  14.Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107:1141–51.PubMed CrossRef
  15.Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35.PubMed CrossRef
  16.Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104:1381–5.PubMed CrossRef
  17.Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71–6.PubMed CrossRef
  18.Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–8.PubMed CrossRef
  19.Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20:73–8.PubMed CrossRef
  20.Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–90.PubMed CrossRef
  21.Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Experi Allergy. 2004;34:632–8.CrossRef
  22.Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709–17.PubMed CrossRef
  23.Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–61.PubMed CrossRef
  24.Subramaniam A, Al-Alawi M, Hamad S, O'Callaghan J, Lane SJ. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland. QJM. 2013;106:631–4.PubMed CrossRef
  25.Gouder C, West LM, Montefort S. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Inter J Clin Pharma. 2015;37:36–43.CrossRef
  26.Caminati M, Senna G, Chieco Bianchi F, Marchi MR, Vianello A, Micheletto C, et al. Omalizumab management beyond clinical trials: the added value of a network model. Pul Pharma Therap. 2014;29:74–9.CrossRef
  27.Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410–6.PubMed CrossRef
  28.Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–31.PubMed CrossRef
  29.Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49:78–82.PubMed CrossRef
  30.Molimard M, Mala L, Bourdeix I, Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108:571–6.PubMed CrossRef
  31.Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123:107–13. e103.PubMed CrossRef
  32.Kuprys-Lipinska I, Kuna P. Loss of asthma control after cessation of omalizumab treatment: real life data. Postepy dermatologii i alergologii. 2014;31:1–5.PubMed PubMedCentral
  33.Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Irish J Med Science. 2011;180:637–41.CrossRef
  
• 作者单位：Hao-Cheng Chen (1)
  Chien-Da Huang (2) (4)
  Erin Chang (3)
  Han-Pin Kuo (2)
  
  1. Department of Internal Medicine, Saint Paul’s Hospital, Taoyuan, Taiwan
  2. Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, Taiwan
  4. Department of Thoracic Medicine and Medical Education, Chang Gung Memorial Hospital, 199 Tun Hwa N. Rd., Taipei, Taiwan
  3. Master of Medicine Management (M.M.M.); Assistant HEOR Manager, Novartis, Taiwan
  
• 刊物主题：Pneumology/Respiratory System; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2466

文摘

Background Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and medical resource utilization of omalizumab in the real-life setting in Taiwan.